Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Reduced mortality after allogeneic hematopoietic-cell transplantation.

Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB.

N Engl J Med. 2010 Nov 25;363(22):2091-101. doi: 10.1056/NEJMoa1004383.

PMID:
21105791
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R.

Blood. 1998 Feb 1;91(3):756-63.

PMID:
9446633
[PubMed - indexed for MEDLINE]
Free Article
3.

Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia.

Bacigalupo A, Van Lint MT, Valbonesi M, Lercari G, Carlier P, Lamparelli T, Gualandi F, Occhini D, Bregante S, Valeriani A, Piaggio G, Pitto A, Benvenuto F, Figari O, De Stefano G, Caimo A, Sessarego M.

Blood. 1996 Jul 1;88(1):353-7.

PMID:
8704195
[PubMed - indexed for MEDLINE]
Free Article
4.

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2012 Sep 12;9:CD009159. doi: 10.1002/14651858.CD009159.pub2. Review.

PMID:
22972135
[PubMed - indexed for MEDLINE]
5.

Allogeneic transplantation for patients with advanced acute leukemia: a single center retrospective study of 92 patients.

Boiron JM, Lerner D, Pigneux A, Fabères C, Bordessoule D, Turlure P, Cony-Makhoul P, Hau F, Dazey B, Agape P, Reiffers J, Marit G.

Leuk Lymphoma. 2001 Apr;41(3-4):285-96.

PMID:
11378541
[PubMed - indexed for MEDLINE]
6.

Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.

Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S, Raiola AM, di Grazia C, Dominietto A, Tedone E, Piaggio G, Podesta M, Bruno B, Oneto R, Lombardi A, Frassoni F, Rolla D, Rollandi G, Viscoli C, Ferro C, Garbarino L, Van Lint MT.

Haematologica. 2004 Oct;89(10):1238-47.

PMID:
15477210
[PubMed - indexed for MEDLINE]
Free Article
7.

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.

Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R.

Bone Marrow Transplant. 2000 May;25(10):1021-8.

PMID:
10828860
[PubMed - indexed for MEDLINE]
Free Article
8.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

PMID:
11801465
[PubMed - indexed for MEDLINE]
Free Article
9.

Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.

Zhang XH, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Chen YH, Wang JZ, Han W, Lu DP.

Chin Med J (Engl). 2007 Mar 20;120(6):463-8.

PMID:
17439737
[PubMed - indexed for MEDLINE]
Free Article
10.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

PMID:
9573003
[PubMed - indexed for MEDLINE]
Free Article
11.

Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation.

Goerner M, Weber-Nordt R, Hoepfner S, Benner A, Luft T, Ho AD.

J Hematother Stem Cell Res. 2003 Jun;12(3):309-20.

PMID:
12857372
[PubMed - indexed for MEDLINE]
12.

Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.

Cao TM, Kusnierz-Glaz C, Valone F, Stockerl-Goldstein KE, Hu WW, Johnston L, Blume KG, Strober S, Negrin RS.

Cancer. 2001 Jun 15;91(12):2205-13.

PMID:
11413507
[PubMed - indexed for MEDLINE]
13.

Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.

Kröger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T; MDS Subcommittee of the Chronic Leukemia Working Party (CLWP) of the European Group for Blood and Marrow Transplantation (EBMT).

Haematologica. 2011 Feb;96(2):291-7. doi: 10.3324/haematol.2010.031229. Epub 2010 Oct 22.

PMID:
20971823
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.

Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, Maris MB, Laport GG, Chauncey TR, Lange T, Langston AA, Storer B, Georges GE.

Haematologica. 2011 Aug;96(8):1113-20. doi: 10.3324/haematol.2011.040261. Epub 2011 Apr 20.

PMID:
21508120
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.

Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A.

Blood. 2000 Jul 1;96(1):80-5.

PMID:
10891434
[PubMed - indexed for MEDLINE]
Free Article
17.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

PMID:
19135940
[PubMed - indexed for MEDLINE]
18.

Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.

Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.

J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17.

PMID:
18086801
[PubMed - indexed for MEDLINE]
19.

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.

Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.

Biol Blood Marrow Transplant. 2001;7(4):230-8.

PMID:
11349810
[PubMed - indexed for MEDLINE]
20.

Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.

Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socié G.

J Clin Oncol. 2011 Jun 1;29(16):2230-9. doi: 10.1200/JCO.2010.33.7212. Epub 2011 Apr 4.

PMID:
21464398
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk